Published in Medical Device Law Weekly, October 10th, 2004
The company's license to U.S. patent no. 5,977,144 provides exclusive composition-of-matter and method-of-use rights to a family of compounds known as cinnamylidene-anabaseines. These compounds target and stimulate the nicotinic alpha-7 cholinergic receptor. Preclinical studies have demonstrated that the alpha-7 receptor on the macrophage cell plays an important role in regulating the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.